The FDA granted BioMarin orphan status for its treatment of alpha-1 antitrypsin deficiency.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- BioMarin closes reimbursement agreement with German insurance fund for Roctavian
- Block upgraded, Bristol Myers downgraded: Wall Street’s top analyst calls
- BioMarin initiated with an Overweight at Wells Fargo
- Biotech Alert: Searches spiking for these stocks today
- BioMarin (NASDAQ:BMRN) Gains after Elliott Investment Picks Up Stake
